Treatment of Early Non–Small Cell Lung Cancer: A New Vigilance for Neoadjuvant Therapy

Jeffrey Thiboutot, MD, MHS


August 09, 2022

Jeffrey Thiboutot, MD, MHS, comments on the recent determination that neoadjuvant chemotherapy for early non–small cell lung cancer is associated with improved outcomes.

The effective use of neoadjuvant regimens, importantly, is reliant upon a thorough diagnosis, which requires enhanced methods of biopsy in order to perform next-generation sequencing. This in turn yields a more precise understanding of the mutations involved in a particular case of cancer and, hence, a more precise course of treatment.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.